NCT02160548

Brief Summary

We hypothesize that salbutamol will speed removal of alveolar fluid compared to atropine alone in OP poisoned patients. We propose to compare the effect of two stat doses of nebulized salbutamol (2.5 mg; 5.0 mg), with nebulized saline placebo, in symptomatic patients receiving standard resuscitation with atropine, oxygen, and fluids after poisoning with OP pesticides. 25 patients will be randomised to each arm (total 75 patients). Primary outcome will be oxygen saturation's over the following 60 min during resuscitation. Secondary outcomes will include atropine dose administered, speed to stabilization, aspiration or pneumonia, intubation, tachydysrhythmias, and mortality. A positive outcome will result in design of a large definitive phase III study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Apr 2015

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 10, 2014

Completed
10 months until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

December 29, 2015

Status Verified

December 1, 2015

Enrollment Period

8 months

First QC Date

June 7, 2014

Last Update Submit

December 28, 2015

Conditions

Keywords

Organophosphate, insectiside, Salbutamol, Atropine

Outcome Measures

Primary Outcomes (1)

  • Improvement of oxygen saturation

    Improvement of oxygen saturation from the base line to normal level after adding nebulized salbutamol to regular I/V atropine and oxygen therapy.

    60 minutes

Secondary Outcomes (1)

  • Heart rate, respiratory rate and Blood pressure

    60 minutes

Other Outcomes (1)

  • Atropine dose

    120 minutes

Study Arms (3)

'Standard care'

PLACEBO COMPARATOR

Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.

Drug: Standard care

'Standard care+ 2.5 mg Salbutamol'

EXPERIMENTAL

Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care

Drug: Standard care+ 2.5 mg Salbutamol

'Standard care+ 5 mg Salbutamol'

EXPERIMENTAL

Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care

Drug: Standard care+ 5 mg Salbutamol

Interventions

Standard management for OP poisoning

Also known as: Intravenous fluids, Intubation if necessary,, Mechanical ventilation if necessary (Engstrom Pro), Atropine (anti-muscarinic; G-Atropine), Pralidoxime (acetylcholinesterase reactivating oxime; PAM-A), Oxygen by face mask by intravenous route,
'Standard care'

Ventolin respiratory solution 2.5 mg

Also known as: Ventolin
'Standard care+ 2.5 mg Salbutamol'

Ventolin respiratory solution 5 mg

Also known as: Ventolin
'Standard care+ 5 mg Salbutamol'

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • age 12 yrs or older
  • clinical features of OP poisoning
  • requiring oxygen and atropine and give consent

You may not qualify if:

  • age 11 yrs or younger
  • no requirement for atropine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sylhet M.A.G.Osmani Medical College Hospital

Sylhet, Sylhet Division, 3100, Bangladesh

Location

Related Publications (4)

  • Abedin MJ, Sayeed AA, Basher A, Maude RJ, Hoque G, Faiz MA. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. J Med Toxicol. 2012 Jun;8(2):108-17. doi: 10.1007/s13181-012-0214-6.

    PMID: 22351300BACKGROUND
  • Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. doi: 10.1016/S0140-6736(07)61202-1.

    PMID: 17706760BACKGROUND
  • Gunnell D, Eddleston M, Phillips MR, Konradsen F. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health. 2007 Dec 21;7:357. doi: 10.1186/1471-2458-7-357.

    PMID: 18154668BACKGROUND
  • Eddleston M. Patterns and problems of deliberate self-poisoning in the developing world. QJM. 2000 Nov;93(11):715-31. doi: 10.1093/qjmed/93.11.715.

    PMID: 11077028BACKGROUND

MeSH Terms

Conditions

Organophosphate Poisoning

Interventions

Standard of CareAtropinepralidoximeAlbuterol

Condition Hierarchy (Ancestors)

PoisoningChemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationAtropine DerivativesTropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-RingEthanolaminesAmino AlcoholsAlcoholsAminesPhenethylaminesEthylamines

Study Officials

  • Fazle R Chowdhury, FCPS

    Consultant, Medicine, Sylhet M.A.G.Osmani Medical Collge, Sylhet, Bangladesh

    PRINCIPAL INVESTIGATOR
  • Michael Eddleston, PhD

    Professor of Clinical Toxicology, University of Edinburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant, Medicine

Study Record Dates

First Submitted

June 7, 2014

First Posted

June 10, 2014

Study Start

April 1, 2015

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

December 29, 2015

Record last verified: 2015-12

Locations